A prediction model using only AMH levels and maternal age identified 79% of women who achieved a live birth through IVF, though it over-predicted success in many cases.
79.2% sensitivityThe AMH + age model correctly identified nearly 4 out of 5 women who achieved a live birth through IVF
What the researchers found
Among all patient characteristics examined, only two factors predicted live birth after IVF: maternal age and serum anti-Müllerian hormone (AMH) concentration. A prediction model based solely on these two variables identified live births with 79.2% sensitivity but only 44.2% specificity.
The model allowed moderate distinction between couples with good versus poor IVF prognosis. AMH, a peptide hormone produced by ovarian follicles that reflects ovarian reserve, proved to be one of the most valuable markers for predicting IVF success alongside age.
Why it matters
Predicting which women will have a successful IVF outcome is critically important for counseling, treatment planning, and managing expectations. This study confirmed that AMH — a peptide biomarker measurable with a simple blood test — adds predictive value beyond age alone. For fertility clinics, incorporating AMH into prognostic models helps identify women who may need more aggressive treatment protocols or who have particularly favorable odds.
The numbers in context
79.2% sensitivity · 44.2% specificity · Only AMH + age predicted live birth · IVF cycles from 2005-2008
How the study worked
Researchers analyzed a database of first-time IVF cycles performed between 2005 and 2008 at University Hospital in Modena, Italy. They used logistic regression to test which baseline patient characteristics predicted live birth. After identifying AMH and age as the only significant predictors, they built a model using just these two variables and evaluated its sensitivity and specificity for predicting live birth outcomes.
Who was studied
Women undergoing their first IVF cycle at a university hospital in Modena, Italy (2005-2008)
What this study cannot tell us
The model had low specificity (44.2%), meaning it frequently predicted success for women who didn't achieve a live birth. Data came from a single center in Italy from 2005-2008, and IVF techniques have improved since. The abstract doesn't report the total number of cycles analyzed. The model only uses pre-treatment factors and doesn't account for embryo quality or other cycle-specific variables.
How to read the evidence
This is a moderate-grade prognostic study based on retrospective analysis of a clinical database from a single center. While the statistical approach is sound, the low specificity and single-center design limit generalizability.
When this study was published
Published in 2011, this is an older study from a period when AMH testing was still being validated for clinical use. AMH has since become a standard fertility biomarker, and more refined prediction models are now available.
The bigger picture
AMH has become one of the standard blood tests in fertility medicine, and this study was among the early validations of its predictive power for IVF outcomes. Since 2011, AMH testing has been widely adopted worldwide, and more sophisticated prediction models incorporating additional variables have been developed. The core finding — that AMH and age are the two dominant predictors of IVF success — has been confirmed repeatedly.
Questions still open
- Can adding embryo quality or other cycle-specific factors significantly improve prediction beyond AMH and age alone?
- Does this model perform equally well across different ethnic populations and IVF protocols?
- At what AMH threshold should clinicians counsel patients about reduced IVF success probability?
Common questions
What is AMH and why does it predict IVF success?
Why was the model's specificity so low (44.2%)?
Read the original research
Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction.
Reproductive biomedicine online, 22(4), 341-9
Citation
La Marca, A; Nelson, S M; Sighinolfi, G; Manno, M; Baraldi, E; Roli, L; Xella, S; Marsella, T; Tagliasacchi, D; D'Amico, R; Volpe, A. (2011). Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction.. Reproductive biomedicine online, 22(4), 341-9. https://doi.org/10.1016/j.rbmo.2010.11.005